Feb 6, 2019: The U.S. Food and Drug Administration (FDA) has approved Cablivi® (caplacizumab-yhdp) in combination with plasma exchange and immunosuppression for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) in adults. Cablivi is the first FDA approved therapy specifically indicated for the treatment of aTTP. Full press release here.
2018 International TTP Day participant fundraising directly impacts the Foundation's ability to provide ground breaking research funding.
The Ohio State University TTP/aHUS face-to-face meeting was made available to non-local participants to join virtually. On Wednesday November 7th, Dr. Cataland presented a great layman explanation about the role of the ADAMTS13 enzyme in TTP. In addition, he thoughtfully answered questions from both the face-to-face and virtual audiences about TTP triggers, treatments, side effects and more. On an exciting note, he explained the role of a new drug called caplacizumab.
The European Commission has granted marketing authorization for caplacizumab for the treatment of adults experiencing an episode of aTTP on August 31, 2018.
Answering TTP Foundation provided research grant funding to support Dr. Long Zheng which has resulted in two research papers on TTP. Together we are furthering the understanding and coming closer to a targeted treatment for TTP. Congratulations Dr. Long Zheng! And congratulations to all supporters of the Answering TTP Foundation.